You are here

PREMIUM

Some bladder cancer patients benefit from Roche therapy

BT_20160607_ROCHE_2320915.jpg
Results of the mid-stage trial could help make the case that Roche's drug should become the first option therapy of choice for patients with metastatic bladder cancer, says a researcher leading the study.

Chicago

A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.

Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes